Fixed versus flexible gonadotropin-releasing hormone antagonist administration in in vitro fertilization: A randomized controlled trial

Fertility and Sterility

Volumn 95, Issue 2, 2011, Pages 558-562

  Kolibianakis, Efstratios M ^a   Venetis, Christos A ^a   Kalogeropoulou, Lydia ^a   Papanikolaou, Evangelos ^b   Tarlatzis, Basil C ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Genesis Hospital   (Greece)

Author keywords

Gonadotropin releasing hormone antagonists; in vitro fertilization; luteinizing hormone surge

Indexed keywords

CETRORELIX; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; NIDATION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; INFERTILITY; LUTEINIZING HORMONE; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE;

EID: 78751566743     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2010.05.052     Document Type: Article

References (17)

1. E.M. Kolibianakis, B. Tarlatzis, and P. Devroey GnRH antagonists in IVF Reprod Biomed Online 10 2005 705 712
2. E.M. Kolibianakis, J. Collins, B.C. Tarlatzis, P. Devroey, K. Diedrich, and G. Griesinger Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis Hum Reprod Update 12 2006 651 671
3. European and Middle East Orgalutran Study Group Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation Hum Reprod 16 2001 644 651
4. C. Albano, R.E. Felberbaum, J. Smitz, H. Riethmuller-Winzen, J. Engel, K. Diedrich European Cetrorelix Study Group Ovarian stimulation with hMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin Hum Reprod 15 2000 526 531
5. G. Borm, B. Mannaerts European Orgalutran Study Group Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial Hum Reprod 15 2000 1490 1498
6. M. Fluker, J. Grifo, A. Leader, M. Levy, D. Meldrum, and S.J. Muasher Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation Fertil Steril 75 2001 38 45
7. F. Olivennes, J. Belaisch-Allart, J.C. Emperaire, H. Dechaud, S. Alvarez, and L. Moreau Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin) Fertil Steril 73 2000 314 320
8. E. Escudero, E. Bosch, J. Crespo, C. Simon, J. Remohi, and A. Pellicer Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients Fertil Steril 81 2004 562 566
9. M.H. Mochtar The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI Hum Reprod 19 2004 1713 1718
10. M. Ludwig, A. Katalinic, C. Banz, A.K. Schroder, M. Loning, and J.M. Weiss Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study Hum Reprod 17 2002 2842 2845
11. E.M. Kolibianakis, C. Albano, J. Kahn, M. Camus, H. Tournaye, and A.C. Van Steirteghem Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy Fertil Steril 79 2003 873 880
12. H. Al-Inany, M.A. Aboulghar, R.T. Mansour, and G.I. Serour Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol Reprod Biomed Online 10 2005 567 570
13. E. Kolibianakis, C. Albano, K. Zikopoulos, J.A. Kahn, A. Van Steirteghem, and P. Devroey GnRH antagonists in poor responders Acta Obstet Gynecol Scand 83 2004 1216 1217
14. P. Devroey, and A. van Steirteghem A review of ten years experience of ICSI Hum Reprod Update 10 2004 19 28
15. P. Devroey, K. Tjandraprawira, B. Mannaerts, H. Coelingh Bennink, J. Smitz, and M. Bonduelle A randomized, assessor-blind, group-comparative efficacy study to compare the effects of Normegon and Metrodin in infertile female patients undergoing in-vitro fertilization Hum Reprod 10 1995 332 337
16. E. Loumaye The control of endogenous secretion of LH by gonadotrophin-releasing hormone agonists during ovarian hyperstimulation for in-vitro fertilization and embryo transfer Hum Reprod 5 1990 357 376
17. I.E. Messinis, D. Loutradis, E. Domali, C.P. Kotsovassilis, L. Papastergiopoulou, and A. Kallitsaris Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment Hum Reprod 20 2005 3192 3197